Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | LPL | P06858 | 2/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671720 | 0.92 | TDP1 (0.44) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL2181233 | 0.90 | LPL (0.43) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL9860710 | 0.90 | LPL (0.43) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL80925 | 0.89 | TP53 (0.41) | TDP1MEN1KMT2ANOS1LPL | |
| SCHEMBL7597599 | 0.89 | ALOX15 (0.50) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL7598359 | 0.89 | ALOX15 (0.39) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL18761741 | 0.89 | TDP1 (0.48) | TDP1MEN1KMT2ANOS1CYP2D6 | |
| SCHEMBL82275 | 0.86 | TAAR1 (0.61) | TDP1TAAR1CYP2D6MAOBCYP1A2 | |
| SCHEMBL8830150 | 0.84 | TDP1 (0.38) | TDP1MEN1KMT2ANOS1TAAR1 | |
| SCHEMBL7899949 | 0.84 | MAOB (0.61) | TDP1NOS1TAAR1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116212960-B | Aryloxy cyclic ether skeleton metal complex catalyst and preparation method and application thereof | 万华化学集团股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-118903087-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-114126593-B | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease | 埃斯佩尔维塔治疗股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| EP-4003314-B1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-116212960-A | Aryloxy cyclic ether skeleton metal complex catalyst and preparation method and application thereof | 万华化学集团股份有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4003314-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | Espervita Therapeutics, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021021563-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
| US-7557126-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-11-01 | — | — | US | disclosed |
| US-7250414-B2 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| WO-2005087763-A9 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | disclosed |
| US-4223172-A | DEHYDROGENATION HALOGENATIVE WITH PALLADIUM-PHOSPHINE COMPLEX CATALYST | GULF RESEARCH & DEVELOPMENT COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
| US-3939084-A | Functional fluid compositions containing substituted pyrimidines | MONSANTO COMPANY (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166177-A1 | BIS-QUATERNARY AMMONIUM SALTS AS PAIN MODULATING AGENTS | RELA, FHIT, OPRL1 | TDP1 2472/4885MEN1 4525/4885KMT2A 1331/4885 |
| US-20050203167-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | TDP1 3041/4885MEN1 1011/4885KMT2A 1381/4885 |
| US-20070254943-A1 | Diphenylmethyl compounds useful as muscarinic receptor antagonists | CHRM1, CHRM2, CHRM3 | TDP1 3041/4885MEN1 1011/4885KMT2A 1381/4885 |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | TDP1 1731/4885MEN1 4255/4885KMT2A 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.